India Human Papillomavirus Vaccine Market: Industry Size and Growth Trends [2029]
Comunicato Precedente
Comunicato Successivo
Introduction
According to the TechSci Research report, “India Human Papillomavirus Vaccine Market - By Region, Competition, Forecast, and Opportunities, 2029,” the human papillomavirus vaccine market in India is anticipated to grow at an impressive rate during the forecast period. This growth can be attributed to the rising uptake of multi-valent human papillomavirus (HPV) vaccines.
Industry Key Highlights
The India human papillomavirus vaccine market witnessed a substantial increase in recent years. Multi-valent HPV vaccines are designed to protect against several strains of HPV, compared to the bivalent vaccine that protects against only two strains. The quadrivalent HPV vaccine and the nonavalent HPV vaccine are two multi-valent vaccines currently available in India. These vaccines provide protection against more strains of HPV, including those associated with a higher risk of cervical cancer.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on the “India Human Papillomavirus Vaccine Market”
HPV and Its Impact
HPV is a group of more than 200 related viruses, with sexually transmitted types falling into two groups: low risk and high risk. High-risk HPVs can cause several types of cancer. HPV infection is common, with nearly all sexually active people infected within months to a few years of becoming sexually active. Most HPV infections do not cause cancer, as the immune system usually clears them. However, about 1% of persistent high-risk HPV infections can cause cancer. HPV infection is a well-established cause of cervical cancer and is increasingly recognized as an important factor in other anogenital cancers (anus, vulva, vagina, and penis) as well as head and neck cancers.
Burden of Cervical Cancer in India
India has a population of 511.4 million women aged 15 years and older who are at risk of developing cervical cancer. Persistent infection with one of the 14 high-risk HPV types causes almost all cervical cancers. HPV types 16 and 18 account for 73% of cervical cancers globally and 80-85% in India. Cervical cancer is the second most common cancer in India, with an estimated 123,907 new cases and 77,348 deaths annually (Globocan 2020), representing close to one-fifth of the global burden. Most cases are diagnosed at a locally advanced clinical stage, with poor survival prospects.
Emerging Trends
Increased Awareness and Accessibility
The uptake of multi-valent HPV vaccines in India has been driven by increased awareness of the risks associated with cervical cancer, greater access to healthcare services, and the introduction of newer and more effective vaccines. Public-private partnerships have been emphasized to develop and distribute HPV vaccines, fostering innovation, reducing costs, and increasing access.
Government and NGO Initiatives
Governments, NGOs, and healthcare organizations are working to increase access to HPV vaccines in India, especially in rural areas where healthcare infrastructure is limited. Various initiatives, such as mobile clinics, awareness campaigns, and subsidized vaccine programs, aim to address these challenges.
Online Market Growth
The online market for human papillomavirus products and services is growing rapidly in India. With the increasing use of digital technology, patients are seeking health information and purchasing health products online. This trend has extended to the HPV vaccine market, with patients using online platforms to buy HPV vaccines, diagnostic tests, and treatments. The COVID-19 pandemic has further accelerated this growth, as social distancing measures and lockdowns have made access to traditional healthcare facilities more difficult.
Drivers of Market Growth
High Burden of Cervical Cancer
The high burden of cervical cancer in India is expected to significantly boost the demand for HPV vaccines. Cervical cancer ranks as the second most frequent cancer among women in India and among women aged 15-44.
Government Funding and Programs
Government initiatives to fund HPV vaccines and rising screening and immunization programs are expected to drive market growth. For instance, various countries have launched fully funded HPV vaccination programs for specific age groups, and similar initiatives in India are expected to bolster market growth.
Public-Private Partnerships
Public-private partnerships formed to develop and distribute HPV vaccines in India are expected to drive innovation, reduce costs, and increase access to these products over the forecast period.
Competitive Analysis
The India human papillomavirus vaccine market is highly competitive, with several key players operating in the sector. Major companies include:
- Bharat Biotech International Ltd.
- GlaxoSmithKline Pharmaceuticals Limited
- MSD Pharmaceuticals Private Limited
- Serum Institute of India Pvt. Ltd.
- HLL Lifecare Limited
- Panacea Biotec Ltd.
Top 10 Companies
Bharat Biotech International Ltd.
Bharat Biotech is a leading biotechnology company in India, known for its innovation in vaccine development. The company has a significant presence in the HPV vaccine market.
GlaxoSmithKline Pharmaceuticals Limited
GSK is a global healthcare company with a strong focus on developing vaccines. Its HPV vaccines are widely used in India.
MSD Pharmaceuticals Private Limited
MSD, known globally as Merck & Co., is a major player in the HPV vaccine market with its Gardasil range of vaccines.
Serum Institute of India Pvt. Ltd.
Serum Institute is one of the world's largest vaccine manufacturers and has a significant presence in the HPV vaccine market in India.
HLL Lifecare Limited
HLL Lifecare is a government-owned corporation that manufactures a range of healthcare products, including vaccines.
Panacea Biotec Ltd.
Panacea Biotec is a leading biotechnology company in India with a focus on vaccine development. It is involved in collaborations to develop and distribute HPV vaccines.
Recent Developments
- In 2020, MSD entered into a collaboration with Indian Immunological Limited (IIL) to expand access to Gardasil 9, a multi-valent HPV vaccine, in India. Under the collaboration, IIL will distribute the vaccine in India.
- In 2019, Panacea Biotec announced a collaboration with Serum Institute of India to develop and manufacture a quadrivalent HPV vaccine, currently in clinical trials.
Future Outlook
The future outlook for the India human papillomavirus vaccine market is positive. The market is expected to grow significantly, driven by increasing awareness of HPV-related diseases, government initiatives, and the growth of the online market for healthcare products. Public-private partnerships and innovative distribution strategies will also play a crucial role in expanding access to HPV vaccines in India.
10 Benefits of the Research Report
- Comprehensive Market Analysis: Detailed insights into the market dynamics, including drivers, restraints, and opportunities.
- Key Trends Identification: In-depth analysis of emerging trends shaping the market.
- Competitive Landscape: Detailed profiles of major companies operating in the market.
- Market Segmentation: Analysis of the market by valence, disease indication, distribution channel, and region.
- Future Market Forecast: Projections for market growth and trends up to 2029.
- Government Initiatives: Insights into government programs and funding initiatives supporting the market.
- Healthcare Infrastructure: Examination of the impact of healthcare infrastructure on market growth.
- Public-Private Partnerships: Analysis of collaborative efforts driving innovation and access.
- Digital Transformation: Assessment of the impact of digital technology on market dynamics.
- Regulatory Environment: Overview of the regulatory landscape affecting the market.
The India human papillomavirus vaccine market is poised for substantial growth in the coming years. With a high burden of HPV-related diseases, significant government and NGO initiatives, and the rise of digital healthcare platforms, the market is set to expand significantly. Collaboration between public and private sectors will be essential in ensuring wider access to vaccines and achieving better health outcomes for the population.
Customers can also request 10% free customization on this report.
“The India human papillomavirus vaccine market is expected to gain substantially from the rising in cancer cases caused by Papillomavirus, such as vulva cancer, vagina cancer, oropharynx cancer (back of throat including base of tongue and tonsils). Furthermore, this market is in its nascent stage and is expected to experience significant growth in the coming years. The inclusion of human papillomavirus vaccines in the national immunization program and the increasing awareness about cervical cancer prevention are likely to play an important role in driving the growth in this market. Besides, rising concerns about healthy lifestyles and increasing expenditure on health and wellness are further expected to create lucrative opportunities for the market’s growth over the forecast period,” said Mr. Karan Chechi, Research Director at TechSci Research, a research-based global management consulting firm.
India Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunities, 2029 has evaluated the future growth potential of the India human papillomavirus vaccine market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the India human papillomavirus vaccine market.
Related Reports-
Trypsin-EDTA Solution for Cell Dissociation Market
UAE Intragastric Balloons Market
India Respiratory Care Devices Market
Contact
US -
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
